Multi-society consensus defines alpha-1 antitrypsin deficiency liver disease by liver enzyme rises and/or fibrosis ≥F2, prefers elastography for staging (≥8 kPa threshold), and sets ≥1-stage fibrosis improvement as the primary trial endpoint.
Guideline
Loomba et al. Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease